Micafungin Reig Jofre Uk (Micafungin)

Micafungin inhibits the fungal enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesizing β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. By blocking this pathway, micafungin weakens the cell wall, leading to osmotic instability and cell death, providing a fungicidal effect against susceptible Candida organisms.

The specific dose of micafungin is determined by the prescribing clinician based on the indication, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals set the appropriate regimen and infusion rate according to approved guidelines and individual patient needs.

Safety data for micafungin in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should discuss potential exposure with their healthcare provider before continuing therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

Micafungin, an echinocandin, offers a fungicidal mechanism distinct from azole antifungals, which are typically fungistatic. Echinocandins have a favorable safety profile regarding hepatic toxicity and drug‑drug interactions, making them a preferred option for patients with liver impairment or those receiving multiple concomitant medications.

Micafungin should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and potency.

Micafungin is supplied as an injectable solution for intravenous infusion. The infusion is typically administered over a period of 30 to 60 minutes, depending on the prescribed dose and clinical protocol, under the supervision of qualified healthcare personnel.

Serious adverse events include severe hepatic failure, anaphylactic reactions, Stevens‑Johnson syndrome or toxic epidermal necrolysis, acute renal impairment, marked hypotension, and cardiac arrhythmias. Patients should be monitored closely for signs of liver dysfunction, hypersensitivity, or cardiovascular instability during therapy.

Micafungin is contraindicated in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is advised for patients with severe hepatic impairment, and it should be avoided in those with a history of severe allergic reactions to echinocandins.